Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.40 |
| ▸ | MMP1 | P03956 | 9/20 | 0.40 |
| ▸ | MMP3 | P08254 | 9/20 | 0.40 |
| ▸ | BMP1 | P13497 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13351183 | 0.92 | CA2 (0.44) | MMP2MMP1MMP3CA1CA2 | |
| SCHEMBL20414883 | 0.92 | CA2 (0.44) | MMP2MMP1MMP3CA1CA2 | |
| SCHEMBL17377402 | 0.86 | MMP3 (0.44) | MMP2MMP1MMP3MMP9MMP7 | |
| SCHEMBL13494792 | 0.85 | MMP3 (0.47) | MMP2MMP1MMP3MMP9MMP7 | |
| SCHEMBL13494786 | 0.85 | MMP3 (0.47) | MMP2MMP1MMP3MMP9MMP7 | |
| SCHEMBL26188181 | 0.84 | SIRT6 (0.44) | MMP2MMP1MMP3CTSSCTSK | |
| SCHEMBL19546728 | 0.83 | SIRT6 (0.53) | MMP2MMP1MMP3CTSSCTSK | |
| SCHEMBL26857870 | 0.80 | MMP3 (0.45) | MMP1MMP3CTSSCTSKMMP9 | |
| SCHEMBL13227770 | 0.80 | HDAC7 (0.43) | MMP2MMP1MMP3BMP1CTSS | |
| SCHEMBL25719293 | 0.80 | HDAC7 (0.43) | MMP2MMP1MMP3BMP1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220289750-A1 | HIMASTATIN DERIVATIVES, AND PROCESSES OF PREPARATION THEREOF, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | PCSK9, HMGCR, PCSK7 | MMP2 944/4885MMP1 3300/4885MMP3 2462/4885 |
| US-20220289750-A1 | HIMASTATIN DERIVATIVES, AND PROCESSES OF PREPARATION THEREOF, AND USES THEREOF | PCSK9, HMGCR, PCSK7 | MMP2 944/4885MMP1 3300/4885MMP3 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.